Clinical Trial Detail

NCT ID NCT01657591
Title Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

melanoma

Therapies

Vemurafenib + XL888

Age Groups: adult

Additional content available in CKB BOOST